NCT02035670 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Bleeker-Rovers CP, Vos FJ, de Kleijn EM, Mudde AH, Dofferhoff TS, Richter C, Smilde TJ, Krabbe PF, Oyen WJ, van der Meer JW
A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore). 2007 Jan;86(1):26-38.
Durack DT, Street AC
Fever of unknown origin--reexamined and redefined. Curr Clin Top Infect Dis. 1991;11:35-51. Review.
PETERSDORF RG, BEESON PB
Fever of unexplained origin: report on 100 cases. Medicine (Baltimore). 1961 Feb;40:1-30.
Vanderschueren S, Knockaert D, Adriaenssens T, Demey W, Durnez A, Blockmans D, Bobbaers H
From prolonged febrile illness to fever of unknown origin: the challenge continues. Arch Intern Med. 2003 May 12;163(9):1033-41.
Xiao Y, Zhang J, Zheng B, Zhao L, Li S, Li L
Changes in Chinese policies to promote the rational use of antibiotics. PLoS Med. 2013 Nov;10(11):e1001556. doi: 10.1371/journal.pmed.1001556. Epub 2013 Nov 19.

A Multicenter Prospective，Randomized and Controlled Pilot Study on the Diagnostic Strategy of So-called Two-step Method in Patients With FUO

Clinical trial NCT02035670 - References